Common Misconceptions About Starting a Derma PCD Franchise in India

A significant share of pharma professionals considering a derma PCD franchise in India delay the decision based on assumptions that do not hold up to scrutiny. Some of these assumptions come from outdated information, others from generic franchise advice that does not account for how dermatology specifically works. Indigammy's home page positions the company around a straightforward, WHO-GMP certified franchise model, and clearing up a few common misconceptions helps explain why that model works the way it does.

Misconception One: A Derma Franchise Needs a Pharmacy Background

This is one of the most persistent assumptions, and it is not accurate. A drug license and GST registration are typically required to operate, but neither requires a pharmacy degree. Many successful derma PCD franchise partners come from sales, distribution, or general business backgrounds rather than a clinical one.

Misconception Two: A Broader Product Range Always Means Better Value

Some franchise companies market extremely long product lists as a selling point, and prospective partners sometimes assume more products automatically means a better deal. In practice, a catalog padded with overlapping SKUs across the same therapeutic use does not add real value. What matters is genuine category depth, tablets, capsules, topical treatments, and cosmetic formulations that reflect actual dermatological demand, not a list stretched to look impressive on paper.

Misconception Three: Certification Claims Are Interchangeable

WHO-GMP, ISO, and various other certifications get referenced loosely across the derma franchise space, and prospective partners sometimes assume any certification claim carries the same weight. It does not. A genuine WHO-GMP certified manufacturer applies documented, batch-level quality checks across its entire operation.

Misconception Four: The Manufacturer's Location Determines Reliability

A common but flawed assumption is that a nearby manufacturer is automatically more reliable than one located further away. What determines reliability is consistent dispatch, responsive communication, and documented quality systems, not physical proximity. Indigammy dispatches to franchise partners across India from its Panchkula facility with the same consistency regardless of a partner's location.

Misconception Five: Franchise Support Ends Once the Agreement Is Signed

Some prospective partners assume the manufacturer relationship is mostly transactional after the initial agreement, limited to periodic reordering. A genuine derma PCD franchise partnership includes product literature ready to use with dermatologists, consistent order fulfillment, and structured promotional support built into onboarding.

Misconception Six: Derma and Cosmetic Categories Require Separate Franchise Relationships

Indigammy manufactures across both categories, tablets and capsules, topical dermatology preparations, and cosmetic formulations like face creams and sunscreens, under one certified process, which means a single franchise partnership can reasonably cover both without added complexity.

Misconception Seven: Franchise Territory Is Always Assigned on a First-Come Basis Without Room to Discuss It

Some prospective partners assume operating area is fixed and non-negotiable once a manufacturer publishes it, with no room for discussion. In reality, area availability is typically confirmed directly during the enquiry process, and it is entirely reasonable to ask specific questions about how boundaries are defined and what happens if territory needs adjust over time. Getting this confirmed in writing before signing avoids one of the more common sources of friction between franchise partners and manufacturers later in the relationship.

Why These Misconceptions Persist

Part of the reason these assumptions circulate so widely is that the derma PCD franchise space in India includes a genuine mix of manufacturer-backed companies and resellers coordinating supply from elsewhere. When both types of companies use similar marketing language, it becomes harder for a prospective partner evaluating options to distinguish a real manufacturing relationship from a repackaged one. Generic franchise advice written for retail or food service franchising also gets applied loosely to pharma franchising, even though the underlying business model, regulatory requirements, and prescriber-driven demand structure are meaningfully different.

A Practical Way to Test These Assumptions Yourself

Before signing any derma PCD franchise agreement, it is worth testing a few of these misconceptions directly rather than taking marketing claims at face value. Ask a prospective manufacturer to produce WHO-GMP documentation on the spot, not just reference it. Ask specifically what happens between order placement and delivery, since this is where support commitments are most likely to quietly underdeliver. And ask whether the product range genuinely spans multiple dosage forms and categories, or whether it is concentrated in one narrow area dressed up to look broader. A manufacturer confident in its own operation should be able to answer all three without hesitation or vague reassurance. Doing this before committing to a partnership costs nothing and takes a single conversation, yet it reliably separates manufacturers genuinely confident in their own process from those relying on marketing language to fill the gap left by a claim they cannot actually substantiate. It is a small amount of diligence relative to the cost of discovering these gaps only after a franchise territory is already established and prescriber trust has already been built on a partner's behalf.

Getting Started

Whether you are evaluating your first derma PCD franchise partnership or comparing options against an existing one, Indigammy's home page is the starting point for reviewing the full product range, and the enquiry process confirms pricing, area availability, and franchise terms directly.